- Home
- HRZN vs ALDX Comparison
HRZN vs ALDX Comparison
Compare HRZN & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRZN
- ALDX
- Stock Information
- Founded
- HRZN 2008
- ALDX 2004
- Country
- HRZN United States
- ALDX United States
- Employees
- HRZN N/A
- ALDX N/A
- Industry
- HRZN Finance/Investors Services
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- HRZN Finance
- ALDX Health Care
- Exchange
- HRZN Nasdaq
- ALDX Nasdaq
- Market Cap
- HRZN 341.0M
- ALDX 398.3M
- IPO Year
- HRZN 2010
- ALDX 2014
- Fundamental
- Price
- HRZN $9.47
- ALDX $5.48
- Analyst Decision
- HRZN Hold
- ALDX Strong Buy
- Analyst Count
- HRZN 4
- ALDX 2
- Target Price
- HRZN $9.56
- ALDX $10.00
- AVG Volume (30 Days)
- HRZN 355.4K
- ALDX 901.3K
- Earning Date
- HRZN 03-04-2025
- ALDX 05-01-2025
- Dividend Yield
- HRZN 13.94%
- ALDX N/A
- EPS Growth
- HRZN N/A
- ALDX N/A
- EPS
- HRZN N/A
- ALDX N/A
- Revenue
- HRZN $99,915,000.00
- ALDX N/A
- Revenue This Year
- HRZN $12.95
- ALDX N/A
- Revenue Next Year
- HRZN $8.81
- ALDX N/A
- P/E Ratio
- HRZN N/A
- ALDX N/A
- Revenue Growth
- HRZN N/A
- ALDX N/A
- 52 Week Low
- HRZN $8.46
- ALDX $3.10
- 52 Week High
- HRZN $12.63
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- HRZN 54.27
- ALDX 37.89
- Support Level
- HRZN $9.27
- ALDX $6.30
- Resistance Level
- HRZN $9.36
- ALDX $6.73
- Average True Range (ATR)
- HRZN 0.15
- ALDX 0.52
- MACD
- HRZN 0.03
- ALDX -0.14
- Stochastic Oscillator
- HRZN 88.89
- ALDX 20.71
About HRZN Horizon Technology Finance Corporation
Horizon Technology Finance Corp is a specialty finance company. Its investment objective is to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It lends to and invests in development-stage companies in the technology, life science, healthcare information and services and sustainability industries.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.